Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Second Clinical Medical College, Binzhou Medical University, Yantai, China.
Am J Mens Health. 2023 May-Jun;17(3):15579883231176667. doi: 10.1177/15579883231176667.
To investigate the potential use of cyclooxygenase-2 (COX-2) inhibitors in the treatment of lower urinary tract symptoms (LUTS) in male patients, we conducted a comprehensive meta-analysis. Our study involved the identification and collection of randomized controlled trials (RCTs) from leading databases including PubMed, MEDLINE, EMBASE, and Cochrane Library. The primary objective of this analysis was to evaluate the effectiveness of COX-2 inhibitors for the treatment of LUTS. Our analysis involved six short-term (within 3 months) RCTs involving 707 patients. We found that COX-2 inhibitor treatment significantly improved the International Prostate Symptom Score (IPSS) of patients (mean difference [MD] = -2.99, 95% confidence interval (CI): -3.65 to -2.33, < .00001), nocturia frequency (MD = -1.90; 95% CI: -3.18 to -0.61, = .004), and maximum flow rate (Qmax) (MD = 1.02; 95% CI: 0.06 to 1.98, = .04). However, no significant differences were found between patients in terms of changes in prostate-specific antigen (PSA) (MD = 0.02; 95% CI: -0.39 to 0.43, = .92) and total prostate volume (TPV) (MD = -2.93; 95% CI: -6.45 to 0.59, = .10). Therefore COX-2 inhibitors are an effective treatment for LUTS.
为了探究环氧化酶-2（COX-2）抑制剂在男性下尿路症状（LUTS）治疗中的潜在应用，我们进行了一项全面的荟萃分析。我们的研究包括从主要数据库（包括 PubMed、MEDLINE、EMBASE 和 Cochrane Library）中确定和收集随机对照试验（RCT）。本分析的主要目的是评估 COX-2 抑制剂治疗 LUTS 的有效性。我们的分析包括 6 项短期（3 个月内）RCT，涉及 707 名患者。我们发现 COX-2 抑制剂治疗显著改善了患者的国际前列腺症状评分（IPSS）（平均差值[MD] = -2.99，95%置信区间[CI]：-3.65 至-2.33，<.00001）、夜尿次数（MD = -1.90；95% CI：-3.18 至-0.61，=.004）和最大尿流率（Qmax）（MD = 1.02；95% CI：0.06 至 1.98，=.04）。然而，在前列腺特异性抗原（PSA）（MD = 0.02；95% CI：-0.39 至 0.43，=.92）和总前列腺体积（TPV）（MD = -2.93；95% CI：-6.45 至 0.59，=.10）的变化方面，患者之间没有显著差异。因此，COX-2 抑制剂是治疗 LUTS 的有效方法。
